My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Ceralasertib (AZD-6738)
    Ceralasertib (AZD-6738)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0233
    CAS #: 1352226-88-0Purity ≥98%

    Description: Ceralasertib (formerly AZD6738), a morpholino-pyrimidine-based DNA damage repair agent, is a potent, orally bioavailable and selective inhibitor of ATR (ataxia telangiectasia and rad3 related) kinase with potential antitumor activity. It inhibits ATR with an IC50 of 1 nM. ATR is a serine/threonine protein kinase that is upregulated in various cancer cells. It is currently being investigated in phase I clinical trials for cancer treatment.

    References: Lancet. 2015 Feb 26;385 Suppl 1:S58; Sci Rep. 2015 Aug 27;5:13545.

    Related CAS: 1352280-98-8 (formic acid); 1352226-97-1 (racemate) 

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)412.51
    CAS No.1352226-88-0
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 82 mg/mL (198.7 mM)
    Water: <1 mg/mL
    Ethanol: 41 mg/mL warmed (99.4 mM)
    Solubility (In vivo)10% DMSO+40% propylene glycol+ddH2O: 10mg/mL 

    AZD6738; AZD-6738;AZD 6738

    Chemical Name: (R)-imino(methyl)(1-(6-((R)-3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl)cyclopropyl)-l6-sulfanone


    InChi Code: InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)/t13-,29-/m1/s1

    SMILES Code: C[[email protected]@](=O)(C1(CC1)C2=NC(C3=C4C=CNC4=NC=C3)=NC(N5CCOC[[email protected]]5C)=C2)=N

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: AZD6738 is an orally available morpholino-pyrimidine-based, and selective inhibitor of the ATR (ataxia telangiectasia and rad3 related) kinase with IC50 of 1 nM. ATR is a serine/threonine protein kinase that is upregulated in various cancer cells, it plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress. AZD6738 has potential antineoplastic activity. Upon administration by oral route, AZD6738 selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1, which prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. In an in vitro model capable of reproducing, over 70 hours after the initiation of the treatment with AZD6738, the γH2AX signal was sustained. Stalled replication forks may collapse the formation of DNA double stranded breaks and the activation of the ataxia telangiectasia mutated (ATM) kinase. As a single agent across cancer cell line panels, AZD6738 is active. In cell lines lacking ATM-pathway, the sensitivity of AZD6738 was enhanced.

    Kinase Assay: AZD6738 is a potent inhibitor of ATR kinase activity with an IC50 of 0.001 μM against the isolated enzyme and 0.074 μM against ATR kinase-dependent CHK1 phosphorylation in cells. 

    Cell Assay: AZD6738 is dissolved in DMSO at 30 mM and diluted in DMSO to desired working concentrations. The final DMSO concentration in media for all conditions and controls is 0.1% for AZD6738 dose response experiments, 0.05% for AZD6738 + chemotherapy viability experiments, and 0.025% for all experiments involving 0.3 μM and 1.0 μM doses of AZD6738. 

    In VivoIn ATM-deficient but not ATM-proficient in vivo models, treatment with AZD6738 alone significantly inhibited the activity of tumors in equivalent, tolerated doses. Ionizing radiation (IR) is a DNA damaging inducing agent. When AZD6738 and IR were used together, regression or anti-tumor growth inhibitory activity was observed. In tumor tissue, AZD6738 is associated with a persistent γH2AX staining increase. In normal gut tissue or bone marrow, treatment with AZD6738 only transiently increased the γH2AX staining.
    Animal modelMice 
    Formulation & DosageDissolved in DMSO at a concentration of 25 mg/mL or 50 mg/mL and diluted 1:5 in propylene glycol; Oral gavage at 25 mg/kg (H23) or 50 mg/kg (H460) for 14 consecutive days; the dosing volume is 10 mL/kg.
    ReferencesLancet. 2015 Feb 26;385 Suppl 1:S58; Sci Rep. 2015 Aug 27;5:13545;  2015 Dec 29;6(42):44289-305. 

    These protocols are for reference only. InvivoChem does not independently validate these methods.



    Inhibition of ATR by AZD6738 inhibits growth of NSCLC cells and induces a DNA damage response.  2015 Dec 29;6(42):44289-305. 



    AZD6738 sensitizes NSCLC cell lines to cisplatin and synergizes strongly with cisplatin in ATM-deficient H23 cells.  2015 Dec 29;6(42):44289-305. 


    The combination of AZD6738 and cisplatin causes accumulation of cells in early S-phase and at the G1/S border.  2015 Dec 29;6(42):44289-305. 



    The combination of AZD6738 and cisplatin causes dramatic cell death of ATM-deficient cells independent of the ATM-p53 signaling pathway.  2015 Dec 29;6(42):44289-305. 


    AZD6738 sensitizes ATM knockdown cells to cisplatin.  2015 Dec 29;6(42):44289-305. 


    AZD6738 potentiates cisplatin efficacy in NSCLC xenografts, and the combination causes rapid regression of ATM-deficient H23 tumors.  2015 Dec 29;6(42):44289-305. 


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?